Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19

By sjmartinez • January 21, 2023

Taiwo BO, Chew KW, Moser C, Wohl DA, Daar ES, Li JZ, Greninger AL, Bausch C, Luke T, Hoover K, Neytman G, Giganti MJ, Olefsky M, Javan AC, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM; ACTIV-2/A5401 Study Team. Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19. J Infect Dis. 2023 Jan 20:jiad013. doi: 10.1093/infdis/jiad013. Epub ahead of print. PMID: 36661240.

Tags: antibody, covid-19, Infectious Diseases, polyclonal, Publications, SAB-185, transchromosomic, Treatment

Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Bloomfield GS, Watanabe M, McCallum S, Aberg JA, Awwad A, Campbell TB, Cespedes MS, Chu SM, Currier JS, Diggs MR, Sponseller CA, Fichtenbaum CJ, Lu[...]

Blood pressure trajectories among people with and without HIV in a U.S.-based prospective cohort study

Sadinski LM, Edwards JK, Herce ME, Avery CL, Miller WC, Simpson RJ, Ramirez C, Palella FJ, Brown TT, Detels R, Magnani JW, Levitan EB, Fischl[...]

SPHERES: innovative registry addressing the new era of neuromyelitis optica spectrum disorders (NMOSD) therapy

Bennett JL, Middaugh N, Yeaman MR, Smith TJ, Behne MK, Crabtree M, McLean RR, Pappas DA, Levy M. SPHERES: innovative registry addressing the new era[...]